Loading…
Based on limited metadata, this FDA Warning Letter issued to LeeSar, Inc. on February 18, 2020 concerns drug product manufacturing or distribution. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The letter falls under FDA's drug regulatory authority, though the specific issuing office is not identified in the metadata provided.